Pharming Group N.V./€PHARM
1D1W1MYTD1Y5YMAX
Capital at risk
About Pharming Group N.V.
Pharming Group N.V. is a biotechnology company based in Leiden, Netherlands, focused on developing and commercializing innovative protein replacement therapies and precision medicines. The company's primary product, Ruconest, is an approved treatment for acute hereditary angioedema attacks, utilizing a recombinant form of the C1 esterase inhibitor. Established in 1988, Pharming leverages proprietary transgenic technology to produce human therapeutic proteins in the milk of genetically modified animals. With a strategic emphasis on rare diseases, the company aims to expand its pipeline through ongoing research and development activities. Pharming operates primarily in Europe and the United States, with partnerships and collaborations enhancing its global presence.
- Ticker
- €PHARM
- Sector
- Health
- Primary listing
- AEX
- Employees
- 407
- Headquarters
- Leiden, Netherlands
- Website
- www.pharming.com
PHARM Metrics
BasicAdvanced
€662M
85.37
€0.01
0.06
-
Price and volume
Market cap
€662M
Beta
0.06
52-week high
€1.81
52-week low
€0.84
Average daily volume
7.9M
Financial strength
Current ratio
3.01
Quick ratio
2.309
Long term debt to equity
0.385
Total debt to equity
0.419
Interest coverage (TTM)
2.31%
Profitability
EBITDA (TTM)
28.502
Gross margin (TTM)
86.52%
Net profit margin (TTM)
2.54%
Operating margin (TTM)
6.92%
Effective tax rate (TTM)
41.29%
Revenue per employee (TTM)
€780,200
Management effectiveness
Return on assets (TTM)
3.47%
Return on equity (TTM)
3.65%
Valuation
Price to earnings (TTM)
85.374
Price to revenue (TTM)
2.071
Price to book
2.45
Price to tangible book (TTM)
4.65
Price to free cash flow (TTM)
22.088
Free cash flow yield (TTM)
4.53%
Free cash flow per share (TTM)
0.042
Growth
Revenue change (TTM)
7.84%
Earnings per share change (TTM)
-196.85%
3-year revenue growth (CAGR)
21.11%
10-year revenue growth (CAGR)
40.28%
3-year earnings per share growth (CAGR)
-21.70%
10-year earnings per share growth (CAGR)
-9.79%
Bulls say / Bears say
JOENJA revenue rose 40% year-over year to US$17.9 million in Q2 2026, demonstrating strong uptake of its APDS treatment in the U.S. and early traction in Europe and Japan. (Reuters)
Pharming delivered a positive operating profit in Q2 2026 despite a 3% year-over year revenue decline, reflecting effective cost management and operational discipline. (Reuters)
The company held US$159.5 million in cash and marketable securities at the end of Q2 2026, providing robust liquidity to support JOENJA expansion and ongoing pipeline investments. (Reuters)
Q2 2026 revenue of US$90.2 million missed analyst estimates by about 10.94%, signaling difficulty in accelerating topline growth. (Reuters)
RUCONEST sales fell 10% year-over year to US$72.3 million in Q2 2026, underscoring pressure on its core cash-generating product amid rising competition. (Reuters)
Full-year 2026 revenue guidance was cut by US$30 million to US$375–395 million, implying near-flat growth and reflecting headwinds in its legacy portfolio. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 26 Aug 2026.
Upcoming events
No upcoming events
Funds containing PHARM
AllUSDEURGBP
Fund name | Fund size | €PHARM weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.10% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.10% |
iShares Healthcare Innovation£DRDR | £1B | 0.10% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.05% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.